Marrow fibrosis and its relevance during imatinib treatment of chronic myeloid leukemia
Marrow fibrosis and its relevance during imatinib treatment of chronic myeloid leukemia
复制标题
DOI：
10.1038/sj.leu.2404917
复制
发表时间：
2007-12-01
期刊：
影响因子：
11.4
通讯作者：
Kreipe, H.
中科院分区：
文献类型：
--
作者：
Buesche, G.;Ganser, A.;Kreipe, H.
在慢性粒细胞白血病（CML）中，伊马替尼可以逆转骨髓纤维化（MF）。 MF 的不良预后是否也能得到逆转，以及伊马替尼是否能保证阻止 MF 的发展，目前尚不清楚。 59 名接受≥ 400mg 伊马替尼/天治疗的 Ph+ CML 患者每隔 6 至 12 个月进行一次 MF 检查。伊马替尼有效逆转了初始 MF（P
In chronic myeloid leukemia (CML), imatinib may reverse bone marrow fibrosis ( MF). Whether the unfavorable prognosis of MF is also reversed and whether imatinib guarantees against evolution of MF are unclear as yet. Fifty-nine patients with Ph+ CML treated with >= 400mg imatinib/day were examined for MF in 6- to 12-month intervals. Imatinib effectively reversed initial MF (P